UNSPSC 51143907: Mazindol

This classification denotes a cns stimulant with the molecular formula C16H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C56709M5NH, chemically known as 5-(p-chlorophenyl)-2,5-dihydro-3h-imidazo(2,1-a)isoindol-5-ol but more generally known as mazindol, which bears US NIH Compound Identifier 4020. European Medicines Agency schedules Mazindol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08656MIG.

UNSPSC 51143907 Mazindol is a Commodity code that nominally identifies a specific pharmaceutical product, yet the recent state and local opportunities tagged under it reflect a much broader and heterogeneous pharmaceutical procurement landscape. State and local governments are soliciting controlled pharmaceuticals, over-the-counter products, and ancillary health-related systems through this code — including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracts distributed through authorized wholesalers. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). These jurisdictions approach pharmaceutical procurement through competitive bidding, requests for information to test market capability, and cooperative vehicles that aggregate demand across multiple states and local entities.

The recent activity concentrates in Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS) on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, response due July 26, 2023, under a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capacity information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements, signaling early-stage exploration before formal RFP issuance. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring vendors to supply through three authorized wholesalers with contracts effective July 1, 2026, and evaluating proposals 75 percent on price competitiveness, with 3 percent administrative fee and minimum $2,000,000 professional liability insurance required.